维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

共被期刊论文引用了3次 您的检索式：您选中1篇文献正在查看引证文献汇总

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Update on occult hepatitis B virus infection显示文摘The event of mutations in the surface antigen gene of hepatitis B virus(HBV) results in undetectable hepatitis B surface antigen with positive/negative anti-hepatitis B core(anti-HBc) antibody status in serum and this phenomenon is named occult hepatitis B infection(OBI). The presence of anti-HBc antibody in serum is an important key for OBI tracking, although about 20% of OBI cases are negative for anti-HBc antibody. The diagnosis of OBI is mainly based on polymerase chain reaction(PCR) and real-time PCR assays. However, real-time PCR is a more reliable method than PCR. OBI is a great issue for the public health problem and a challenge for the clinical entity worldwide. The persistence of OBI may lead to the development of cirrhosis and hepatocellular carcinoma. With regard to OBI complications, the screening of HBV DNA by the highly sensitive molecular means should be implemented for:(1) patients with a previous history of chronic or acute HBV infection;(2) patients co-infected with hepatitis C virus/human immunodeficiency virus;(3) patients undergoing chemotherapy or anti-CD20 therapy;(4) recipients of organ transplant;(5) blood donors;(6) organ transplant donors;(7) thalassemia and hemophilia patients;(8) health care workers;(9) patients with liver related disease(cryptogenic);(10) hemodialysis patients;(11) patients undergoing lamivudine or interferon therapy; and(12) children in time of HBV vaccination especially in highly endemic areas of HBV. Active HBV vaccination should be implemented for the close relatives of patients who are negative for OBI markers. Thus, the goal of this review is to evaluate the rate of OBI with a focus on status of high risk groups in different regions of the world.	Manoochehr Makvandi	2016	World Journal of Gastroenterology2016，22，39：	28
	2	多发性骨髓瘤合并HBV感染的临床分析显示文摘目的探讨多发性骨髓瘤合并乙型肝炎病毒(HBV)感染的临床特点。方法选择2010年1月-2016年12月医院多发性骨髓瘤患者250例作为多发性骨髓瘤组,体检者250名作为对照组,多发性骨髓瘤患者根据HBsAg是否阳性分为HBsAg阳性患者22例和HBsAg阴性患者228例;测定HBsAg阳性与阴性患者血清肝炎病毒标记物。结果多发性骨髓瘤组HBsAg阳性率为8.8%,高于对照组的2.8%(P<0.05);多发性骨髓瘤患者中,HBsAg阳性患者肝硬化率高于HBsAg阴性患者(P<0.05);HBsAg阳性患者治疗前、治疗中和治疗后肝损伤比例均高于HBsAg阴性患者(P<0.05);HBsAg阳性患者HBV再激活率高于HBsAg阴性患者(P<0.05)。结论多发性骨髓瘤患者HBsAg阳性率高,多发性骨髓瘤合并HBsAg阳性患者肝硬化、治疗前后肝损伤及HBV再激活率均升高。	颜敏超曾惠李园吴海兵王文松	2017	中华医院感染学杂志2017，27，24：	6

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费